The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
1 clinical trials · Condition
◉ Watch The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
| Record | Firm | Date |
|---|---|---|
| A Prospective Post-Marketing Observational Safety Study of Verzenios® (Abemaciclib) Among Breast Cancer Patients in China Verzenios® (Abemaciclib) Among Breast (NCT05267327) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2022-03-01 |
Track The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks automatically
Every clearance here is in the API, with alerts when new ones post.